The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology

JGF Cleland; Nick Freemantle; SG Ball; Robert Bonser; PG Camici; S Chattopadhyay; D Dutka; Joanne Eastaugh

doi:10.1016/S1388-9842(03)00056-4

The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology

JGF Cleland
, Nick Freemantle
, SG Ball
, Robert Bonser
, PG Camici
, S Chattopadhyay
, D Dutka
, Joanne Eastaugh

Birmingham Medical School

Research output: Contribution to journal › Article

74 Citations (Scopus)

Abstract

BACKGROUND: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. AIMS: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. METHODS: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction

Original language	English
Pages (from-to)	295-303
Number of pages	9
Journal	European Journal of Heart Failure
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/S1388-9842(03)00056-4
Publication status	Published - 1 Jun 2003

Keywords

revascularisation
HEART study
left ventricular systolic dysfunction
heart failure

Access to Document

10.1016/S1388-9842(03)00056-4

Cite this

@article{1ddeb00c49f94210a457c86345aef038,

title = "The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology",

abstract = "BACKGROUND: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. AIMS: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. METHODS: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction ",

keywords = "revascularisation, HEART study, left ventricular systolic dysfunction, heart failure",

author = "JGF Cleland and Nick Freemantle and SG Ball and Robert Bonser and PG Camici and S Chattopadhyay and D Dutka and Joanne Eastaugh",

year = "2003",

month = jun,

day = "1",

doi = "10.1016/S1388-9842(03)00056-4",

language = "English",

volume = "5",

pages = "295--303",

journal = "European Journal of Heart Failure",

issn = "1879-0844",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology

AU - Cleland, JGF

AU - Freemantle, Nick

AU - Ball, SG

AU - Bonser, Robert

AU - Camici, PG

AU - Chattopadhyay, S

AU - Dutka, D

AU - Eastaugh, Joanne

PY - 2003/6/1

Y1 - 2003/6/1

N2 - BACKGROUND: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. AIMS: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. METHODS: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction

AB - BACKGROUND: Most patients with heart failure due to left ventricular systolic dysfunction (LVSD) secondary to coronary artery disease (CAD) have evidence of myocardium in jeopardy (reversible ischaemia and/or stunning hibernation). It is not known whether revascularisation in such cases is safe or beneficial. AIMS: To determine whether revascularisation will improve the survival of patients with LVSD and heart failure secondary to CAD and myocardium in jeopardy. METHODS: This is a randomised controlled trial comparing revascularisation or not, in addition to optimal medical therapy with ACE inhibitors, beta-blockers, aldosterone antagonists and an anti-thrombotic agent. Patients must have heart failure requiring treatment with diuretics, a left ventricular ejection fraction

KW - revascularisation

KW - HEART study

KW - left ventricular systolic dysfunction

KW - heart failure

UR - https://www.scopus.com/pages/publications/0012650167

U2 - 10.1016/S1388-9842(03)00056-4

DO - 10.1016/S1388-9842(03)00056-4

M3 - Article

C2 - 12798827

SN - 1879-0844

VL - 5

SP - 295

EP - 303

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 3

ER -

The Heart Failure Revascularisation Trial (HEART): Rationale, Design and Methodology

Abstract

Keywords

Access to Document

Fingerprint

Cite this